ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO1061

Combining a Heparin-Grafted Dialyzer with a Citrate-Enriched Dialysate Offers Acceptable Dialysis Adequacy Avoiding Systemic Anticoagulation: Results of the Randomized Noninferiority Evocit Study

Session Information

Category: Dialysis

  • 701 Dialysis: Hemodialysis and Frequent Dialysis


  • Francois, Karlien, Vrije Universiteit Brussel, Brussels, Brussels, Belgium
  • De Clerck, Dieter, Vrije Universiteit Brussel, Brussels, Brussels, Belgium
  • Tonnelier, Annelies, Vrije Universiteit Brussel, Brussels, Brussels, Belgium
  • Cambier, Marie-Laure, Vrije Universiteit Brussel, Brussels, Brussels, Belgium
  • Cools, Wilfried, Vrije Universiteit Brussel, Brussels, Brussels, Belgium
  • Wissing, Karl Martin, Vrije Universiteit Brussel, Brussels, Brussels, Belgium

The combined use of a heparin-grafted membrane with a citrate-enriched dialysate is a hemodialysis (HD) strategy with low circuit clotting rates while avoiding systemic anticoagulation. Its adequacy in comparison to HD using systemic anticoagulation is unknown.


Prevalent HD patients were recruited for a randomized crossover non-inferiority trial powered at >90% to detect a prespecified non-inferiority threshold of 10% spKt/Vurea (NCT03887468). HD using a heparin-grafted dialyzer in combination with a 1.0 mmol/L citrate-enriched dialysate (“evocit”) was compared to HD using a heparin-grafted dialyzer, systemic unfractionated heparin and bicarbonate-based dialysate (“evohep”). Each treatment arm lasted 4 weeks: 3x4hours HD/week with fixed blood and dialysate flow rates and midweek biological analyses.


26 patients received 617 HD sessions: 307 evocit and 310 evohep sessions. Mean spKt/Vurea was 1.46±0.23 for evocit and 1.50±0.24 for evohep sessions (p=0.06). Mean of the paired difference in spKt/Vurea was 0.04 with a 95%CI of -0.002 to 0.08, the upper bound of the estimate lying within the prespecified non-inferiority threshold (i.e. <0.15). Urea reduction rate (RR) was 71.5±5.5% vs 72.1±5.7% and bèta2microglobulin RR 37.4±8% vs 37.8±8% for evocit and evohep sessions. Processed blood volume was 75.4±3L vs 75.8±1.5L and online Kt was 47.3±5L vs 48.3±4L for all evocit and evohep sessions. Circuit thrombosis leading to premature treatment end occurred in 13/307 (4.2%) of evocit sessions (n=6), but in none of the evohep sessions (p=0.0002), with a median 36(20-46)min treatment time shortening without impact on effective treatment times overall (236±12 vs 238±4min for evocit vs evohep). Retransfusion failure occurred in 3/307 (0.98%) of evocit sessions and none of the evohep sessions (p=0.25).


HD avoiding systemic anticoagulation using a heparin-grafted dialyzer with a citrate-enriched dialysate offers recommended spKt/Vurea dose and is not inferior to HD using systemic anticoagulation in terms of spKt/Vurea. Circuit clotting complications occurred at low rates during evocit sessions and did not have clinically significant repercussions on dialysis efficacy.


  • Private Foundation Support